Abstract
Pigment epithelium-derived factor (PEDF) has anti-inflammatory and anti-thrombogenic properties both in cell culture and animal models. Although adipose triglyceride lipase (ATGL) and laminin receptor (LR) are two putative receptors for PEDF, which receptor mainly mediates the beneficial effects of PEDF is largely unknown. In this study, we addressed the issue. siRNA raised against LR (siLR) and siATGL transfection dramatically decreased LR and ATGL levels in human cultured myeloma cells, respectively. Ten nM PEDF significantly reduced vascular endothelial growth factor (VEGF), monocyte chemoattractant protein-1 (MCP-1), intercellular cell adhesion molecule-1 (ICAM-1) and plasminogen activator inhibitor-1 (PAI-1) mRNA levels in siCon- or siATGL-transfected myeloma cells, whereas PEDF increased rather than decreased these gene expressions in siLR-transfected cells. Neutralizing antibody directed against LR (LR-Ab) or LR antagonist actually bound to LR and reduced mRNA levels of VEGF, MCP-1, ICAM-1 and PAI-1 in myeloma cells. Further, pre-treatment of LR-Ab or LR antagonist suppressed the binding of PEDF to LR and resultantly blocked the effects of PEDF in myeloma cells. In addition, high concentration of LR agonist mimicked the ...Continue Reading
References
Sep 1, 1991·Experimental Eye Research·J Tombran-TinkL V Johnson
May 16, 1998·Biochemistry·Y OkahataT Morii
Jul 10, 1999·Science·D W DawsonN P Bouck
Aug 30, 2002·Biochemical and Biophysical Research Communications·Sho-ichi YamagishiZenji Makita
Apr 21, 2004·Proceedings of the National Academy of Sciences of the United States of America·Hua LiuPatrick Y Tong
Apr 21, 2006·Microvascular Research·Sho-ichi YamagishiTsutomu Imaizumi
May 19, 2006·The Journal of Biological Chemistry·Sho-ichi YamagishiTsutomu Imaizumi
Oct 13, 2006·The Journal of Biological Chemistry·Luigi NotariS Patricia Becerra
May 26, 2007·The American Journal of Pathology·Kazuo NakamuraTsutomu Imaizumi
Sep 14, 2007·Atherosclerosis·Katsuhiko TakenakaTsutomu Imaizumi
Jan 15, 2008·Journal of Hepatology·Chuhan ChungSusan E Crawford
Jan 24, 2009·Diabetes/metabolism Research and Reviews·Sho-Ichi YamagishiHiroyoshi Inoue
Feb 20, 2009·The Journal of Biological Chemistry·Adrien BernardZhenlin Li
Mar 12, 2009·Current Pharmaceutical Design·Sho-ichi YamagishiKazuo Nakamura
Aug 22, 2009·Expert Opinion on Therapeutic Targets·Kathrin RychliJohann Wojta
Feb 2, 2011·The American Journal of Pathology·Shin-ichiro UedaTsutomu Imaizumi
Mar 16, 2011·Biotechnology and Bioengineering·Delphine Le Guillou-BuffelloVéronique Migonney
Apr 6, 2011·Diabetes·Melissa L BorgMatthew J Watt
Nov 20, 2012·The American Journal of Pathology·Ayako OjimaSho-ichi Yamagishi
Feb 5, 2013·Biochemical and Biophysical Research Communications·Ritsuko SekiTakashi Okamura
May 1, 2013·Diabetes·Yusuke KaidaSho-ichi Yamagishi
Citations
Dec 2, 2015·Oncology Letters·Takanori MatsuiSho-Ichi Yamagishi
Dec 16, 2016·International Journal of Molecular Sciences·Zhongxin ZhouZhongming Zhang
Aug 5, 2017·Cell Death & Disease·Jianjing HouHong Li
Mar 21, 2019·Current Pharmaceutical Design·Sho-Ichi YamagishiMinoru Yagi
Apr 24, 2020·International Journal of Molecular Medicine·Xi ZhangYi Zhang
Oct 10, 2015·Molecular Cancer Therapeutics·Keren GoldbergIrit Ben-Aharon
Sep 15, 2019·Experimental Eye Research·Nader SheibaniJack Henkin
Jul 17, 2021·Oncology Letters·Shiori TsuruhisaSho-Ichi Yamagishi
Aug 2, 2021·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Yu ZhangXianjie Ma